Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Wyles

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Journal of Viral Hepatitis|November 14, 2018
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysisSteven Flamm, David Mutimer, Armen Asatryan, et al.
The New England Journal of Medicine|July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
The Lancet. Respiratory Medicine|October 21, 2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trialAndre C Kalil, Aneesh K Mehta, Thomas F Patterson, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Journal of Hepatology|April 17, 2017
Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosisPaul Y Kwo, Fred Poordad, Armen Asatryan, et al.
Journal of Viral Hepatitis|November 14, 2018
Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysisSteven Flamm, David Mutimer, Armen Asatryan, et al.
The New England Journal of Medicine|July 22, 2015
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1David L Wyles, Peter J Ruane, Mark S Sulkowski, et al.
The Lancet. Respiratory Medicine|October 21, 2021
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trialAndre C Kalil, Aneesh K Mehta, Thomas F Patterson, et al.
Pageof 8